medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (2)

Cytogenetic techniques for the study of leukemias

González GS, Lavaut SK

Language: Spanish
References: 34
Page: 1-15
PDF size: 306.61 Kb.


ABSTRACT

Introduction: Leukemia is defined as a clonal process of hematopoietic cells, which occurs when blood cells that are produced in the bone marrow change and multiply uncontrollably. This is characterized by its genetic heterogeneity and is explained through mechanisms caused by chromosomal alterations that are used in daily clinical practice as useful biomarkers for diagnosis, prognosis or prediction of response to treatment.
Objective: To describe the conventional and molecular cytogenetic techniques used for the diagnosis and monitoring of leukemias.
Methods: A review of the literature in English and in Spanish was carried out, in the PubMed website and using the search engine Google, for articles published in the last five years. We performed analysis and summary of the reviewed bibliography.
Analysis and synthesis of information: Cytogenetics over the years has provided crucial information for the diagnosis and prognosis of hematologic malignancies. Both conventional and molecular cytogenetic techniques such as fluorescent in situ hybridization, multicolor fluorescent in situ hybridization, spectral karyotype, comparative genomic hybridization and microarrays, participate in the recognition of chromosomal and gene alterations, as well as interactions involved in the oncogenesis process.
Conclusions: These cytogenetic techniques contribute to the diagnosis, prognostic stratification and application of treatment according to the type or subtype of leukemia.


REFERENCES

  1. Almeida AL, Azevedo IC, Carvalho DP, Vitor AF, Santos VE, Ferreira Júnior MA. Clinical and epidemiological aspects of leukemias. Rev Cubana Hematol Inmunol Hemoter. 2017 [acceso: 01/07/2021];33(2). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/511 1.

  2. Pérez KP. Caracterización inmunofenotípica y citogenética de pacientes con leucemia mieloide aguda Instituto Nacional de Enfermedades Neoplásicas. [tesis] Lima: Universidad Nacional Federico Villarreal; 2018. [acceso 01/07/2021]. Disponible en: Disponible en: http://repositorio.unfv.edu.pe/bitstream/handle/UNFV/1945/PerezVasquezKellyPatricia.pdf?sequence=1&isAllowed=y 2.

  3. Sitlinger A, Brander DM, Bartlett DB. Impact of exercise on the immune system and outcomes in hematologic malignancies. Blood Adv. 2020;4(8):1801-11. DOI: https://10.1182/bloodadvances.20190013173.

  4. Torres E. Ventajas y limitaciones de la citogenética en la medicina actual. Mem Inst Investig Cienc Salud. 2018;16(2):107-12. DOI: https://10.18004/Mem.iics/1812-9528/2018.016(02)107-1124.

  5. Amor AM, Hernández LL, Díaz CA, Fernández L, Ruíz V, Garrote H. La biología molecular en la precisión diagnóstica de las leucemias. Rev Cubana Hematol Inmunol Hemoter. 2018 [acceso 01/07/2021];34(3). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/882 5.

  6. Swerdlow S, Campo E, Harris N, eds. WHO classification of tumors of haematopoietic and lymphoid tissue. 4th ed. Lyon, France: IARC Press; 2008.

  7. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. DOI: https://10.1182/blood-2016-03-6435447.

  8. Hussain IS, Ghulam JM. Advances in Malignant Hematology. Chichester: Wiley; 2011. [acceso 01/07/2021]. Disponible en: Disponible en: https://www.researchgate.net/publication/292070853Advances_in_Malignant Hematology 8.

  9. Becerra JA, López JB. Citogenética del cáncer; alteraciones cromosómicas útiles para el diagnóstico oportuno y pronóstico en neoplasias linfoproliferativas. Rev Fac Cienc. 2020;9(1):25-54. DOI: https://doi.org/10.15446/rev.fac.cienc.v9n1.745959.

  10. Kang JU. Medical Implementation of Microarray Technology. Korean J Clin Lab Sci. 2020;52:310-6. DOI: https://10.15324/kjcls.2020.52.4.31010.

  11. Blackmon H, Justison J, Mayrose I, Goldberg E. Meiotic drive shapes rates of karyotype evolution in mammals. Evolution. 2019;73(3):511-23. DOI: https://10.1111/evo.1368211.

  12. Hernández M, Dueñas JE. Frecuencia del cromosoma Filadelfia en niños con leucemia linfoblástica aguda. Rev Mex Pediatr. 2020;87(5):170-5. DOI: https://10.35366/9717012.

  13. Arber DA, Orazi A. Diagnosis and classification of the acute leukemias and myelodysplastic syndromes. En: Greer JP, Rodgers GM, Glader P, Arber DA, Means RT, List AF, et al13. . Wintrobe’s clinical hematology. 14th edition. Saint Louis, Missouri: Wolters Kluwer; 2019. p.4851-84.

  14. Huebner T, Scholl C, Steffens M. Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe. Diagnostic. 2021;11(7):1169. DOI: https://doi.org/10.3390/diagnostics1107116914.

  15. Hernando C. Caracterización de anomalías cromosómicas en diagnóstico prenatal y postnatal mediante técnicas de citogenética molecular. [tesis]. Barcelona: Universidad Autónoma de Barcelona; 2006. [acceso 01/07/2021]. Disponible en: Disponible en: https://www.tdx.cat/handle/10803/3761?show=full 15.

  16. Lavaut K. Citogenética de las hemopatías malignas en la era de la secuenciación. Rev Cubana Hematol Inmunol Hemoter. 2020 [acceso 01/07/2021];36(3). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/1243 16.

  17. Cherry AM, Bangs CD. Cytogenetics. En: Greer JP, Rodgers GM, Glader P, Arber DA, Means RT, List AF, et al17. . Wintrobe’s clinical hematology. 14th ed. Saint Louis, Missouri: Wolters Kluwer ; 2019. p. 304-12.

  18. Young AP, Jackson DJ, Wyeth RC. A technical review and guide to RNA fluorescence in situ hybridization. Peer J. 2020; 8:e8806. DOI: https://10.7717/peerj.880618.

  19. Zumoffen C. Hibridación in situ fluorescente Laboratorios CIBIC. 2017 [acceso 01/07/2021]. Disponible en: Disponible en: http://www.cibic.com.ar/laboratorios-bioquimicos/hibridacion-in-situ-fluorescente-fish/ 19. .

  20. Blog de CEDIE. Citogenética convencional y molecular. [actualizado 2021]; [acceso 01/07/2021]; Disponible en: Disponible en: https://cedie.conicet.gov.ar/citogenetica/ 20.

  21. Veselinyová D, Mašlanková J, Kalinová K, Mičková H, Mareková M, Rabajdová M. Selected In Situ Hybridization Methods: Principles and Application. Molecules. 2021;26(13):3874. DOI: https://10.3390/molecules26133874

  22. Riegel M. Human molecular cytogenetics: From cells to nucleotides. Genet Mol Biol Mar. 2014;37(1 Suppl):194-209. DOI: https://10.1590/s1415-47572014000200006

  23. Shakoori AR. Fluorescence In Situ Hybridization (FISH) and Its Applications. Chromosome Structure and Aberrations. 2017:343-67. DOI: https://10.1007/978-81-322-3673-3_16

  24. Pathak R, Koturbash I, Hauer M. Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice. J Vis Exp. 2017 (119):55162. DOI: https://10.3791/55162

  25. Binz RL, Tian E, Sadhukhan R, Zhou D, Hauer M, Pathak R. Identification of novel breakpoints for locus- and region-specific translocations in 293 cells by molecular cytogenetics before and after irradiation. Sci Rep. 2019;9(1):10554. DOI: https://10.1038/s41598-019-47002-0

  26. Tirado CA, Goodman BK. Acta Cancerológica. En: Multicolor FISH: Una herramienta de gran utilidad en el monitoreo de leucemia mieloide aguda y otras malignidades hematológicas. Acta Cencerol. 2003 [acceso 01/07/2021];32(1):40_4. Disponible en: Disponible en: https://sisbib.unmsm.edu.pe/bvrevistas/acta_cancerol%C3%B3gica/v32_n1/multi_fish.htm 26.

  27. Mrózek K, Harper DP, Aplan PD. Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2009;23(5):991. DOI: https://10.1016/j.hoc.2009.07.001

  28. Mraz M, Kozubik KS, Plevova K, Musilova K, Tichy B, Borsky M, et al28. . The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. Leukemia Res. 2013;37(7):802-8. DOI: https://doi.org/10.1016/j.leukres.2013.03.018

  29. Shahjahani M, Hadad EH, Azizidoost S, Nezhad KC, Shahrabi S. Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. Oncol Rev. 2019;13(1):389. DOI: https://10.4081/oncol.2019.389

  30. Kalkan R. The Use of Molecular Cytogenetic Techniques for the Identification of Chromosomal Abnormalities. Intech Open; 2017 [acceso 01/07/2021]. Disponible en: Disponible en: https://www.intechopen.com/chapters/54502 30.

  31. Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, Van der Kevie-Kersemaekers AM, et al31. . Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Hematológica. 2021;106(1):87-97. DOI: https://10.3324/haematol.2019.239947

  32. Blog de Genotipia. Análisis citogenómicos aplicados a neoplasias hematológicas: recomendaciones preanalíticas, analíticas y postanalíticas. 2021 [acceso 01/07/2021]; Disponible en: Disponible en: https://genotipia.com/guias/guia-analisis-citogenomicos-neoplasias-hematologicas/ 32.

  33. Lapirra I. Citogenética humana: del microscopio al microchip. Hematología. 2011 [acceso 01/07/2021];15(2):27-34. Disponible en: Disponible en: http://www.sah.org.ar/revista/numeros/vol15.n2.27-34.pdf 33.

  34. Bint SM, Davies AF, Ogilvie CM. Multicolor banding remains an important adjunct to array CGH and conventional karyotyping. Mol Cytogenet. 2013;6(1):55. DOI: https://10.1186/1755-8166-6-55




2020     |     www.medigraphic.com